1. Aminoff MJ, Parent JM. Comorbidity in Adults. In J Engel Jr, TA Pedley (eds), Epilepsy: a Comprehensive Textbook. Philadelphia: Lippincott–Raven, 1997;1957–1970.

2. Asconapé JJ, Penry JK. Use of antiepileptic drugs in the presence of liver and kidney diseases: a review. Epilepsia 1982;23:S65–S79.

3. Muruve DA, Steinman TI. Contrast-induced encephalopathy and seizures in a patient with chronic renal insufficiency. Clin Nephrol 1996;45:406–409.

4. Kunisaki TA, Augenstein WL. Drug- and toxin- induced seizures. Emerg Med Clin North Am 1994;12:1027–1056.

5. Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993;11:565–568.

6. Shannon M. Ingestion of toxic substances by children. N Engl J Med 2000;342:186–191.

7. Franson KL, Hay DP, Neppe V, et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 1995;7:38–48.

8. Delanty N, Vaughan CJ, French JA. Medical causes of seizures. Lancet 1998;352:383–390.

9. Hirsch LJ, Pedley TA. Perioperative Seizures: Prevention and Management. In H Batjer, C Loftus (eds), Textbook of Neurological Surgery. Philadelphia: Lippincott Williams & Wilkins, 2002.

10. Birnbaum AK, Kriel RL, Burkhardt RT, Remmel RP. Rectal absorption of lamotrigine compressed tablets. Epilepsia 2000;41:850–853.

11. Brown DL, Ransom DM, Hall JA, et al. Regional anesthesia and local anesthetic-induced systemic toxicity: seizure frequency and accompanying cardiovascular changes. Anesth Analg 1995;81:321–328.

12. Petursson H. The benzodiazepine withdrawal syndrome. Addiction 1994;89:1455–1459.

13. Sutherland MJ, Burt P. Propofol and seizures. Anaesth Intensive Care 1994;22:733–737.

14. Terasako K, Ishii S. Postoperative seizure-like activity following sevoflurane anesthesia. Acta Anaest Scand 1996;40:953–954.

15. Lane HY, Su KP, Chang WH. Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects? J Clin Psychiatry 1999;60:408–409.

16. Schulze-Bonhage A, Elger CE. Induction of partial epileptic seizures by flumazenil. Epilepsia 2000;41:186–192.

17. Herishano YO, Zlotnik M, Mostoslavsky M, et al. Cefuroxime-induced encephalopathy. Neurology 1998;50:1873–1875.

18. Koppel B, van Duin D, Samkoff L, et al. Imipenem does not contribute to seizures in severely ill patients if dose is adjusted for renal function. Epilepsia 1997;38[Suppl 8]:S109–S110.

19. Walker RC. The fluoroquinolones. Mayo Clin Proc 1999;74:1030–1037.

20. Koppel BS. Neurologic Complications of AIDS and HIV Infection: an Overview. In: G Wormser (ed), A Clinician's Guide to AIDS and HIV Infection. Philadelphia: Lippincott–Raven, 1996;141–197.

21. Simpson DM, Olney R, McArthur JC, et al. A placebo- controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000;54:2115–2119.

22. Romanelli F, Jennings HR, Nath A, et al. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000;54:1404–1407.

23. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10:281–291.

24. Wong M, Yamada KA. Cyclosporine induces epilepti- form activity in an in vitro seizure model. Epilepsia 2000;41:271–276.

25. Devinsky O. The differential diagnosis of seizures and epilepsy. Semin Neurol 1990;10:321–327.

26. Hillbom M, Tokola R, Kuusela V, et al. Pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents. Neurology 1999;53[Suppl 2]:S89–S95.

27. Koppel BS, Daras M, Tuchman AJ, et al. Relationship between alcohol and seizures in a city hospital population. J Epilepsy 1992;5:31–37.

28. Hillbom M, Tokola R, Kuusela V, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989;6:223–226.

29. Young GP, Rores C, Murphy C, Daily RH. Intravenous phenobarbital for alcohol withdrawal and convulsions. Ann Emerg Med 1987;38:847–850.

30. Bowman ES. Nonepileptic seizures: psychiatric framework, treatment, and outcome. Neurology 1999;53[Suppl 2]:S84–S88.

31. Krumholz A. Nonepileptic seizures: diagnosis and management. Neurology 1999;53[Suppl 2]:S76–S83.

32. Torta R, Keller R. Behavioral, psychotic and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999;40[Suppl 10]:S2–S20.

33. Blumer D. Evidence supporting the temporal lobe epilepsy personality syndrome. Neurology 1999;53[Suppl 2]:S9–S12.

34. Lancman M. Psychosis and peri-ictal confusional states. Neurology 1999;53[Suppl 2]:S33–S38.

35. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219–223.

36. Ehrenberg B. Importance of sleep restoration in co- morbid disease: effect of anticonvulsants. Neurology 2000;54[Suppl 1]:S33–S37.

37. Sammaritano M, Sherwin A. Effect of anticonvulsants on sleep. Neurology 2000;54[Suppl 1]:S16–S24.

38. Trabert W, Hohagen F, Winkelmann G, Berger M. Seizure and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995;28:95–97.

39. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999;40[Suppl 10]:S48–S56.

40. Kanner AM, Rivas Nieto JC. Depressive disorders in epilepsy. Neurology 1999;53[Suppl 2]:S26–S32.

41. Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53[Suppl 2]:S68–S75.

42. Dailey JW, Naritoku, DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996;52:1323–1329.

43. Richelson E. Pharmacology of antidepressants—characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069–1081.

44. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia 1999;40[Suppl 10]:S21–S47.

45. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993;21:197–208.

46. Goldstein L, Barker M, Segall F, et al. Seizure and transient SIADH associated with sertraline [Letter]. Am J Psychiatry 1996;153:732.

47. Ranieri P, Franczoni S, Trabucchi M. Reboxetine and hyponatremia [letter]. N Engl J Med 2000;342:215–216.

48. Bell AJ, Cole A, Eccleston D, Ferrier IN. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993;162:689–692.

49. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997;32[Suppl 1]:S1–S21.

50. Preskorn SH, Fast GA. Tricyclic antidepressant- induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160–162.

51. Baldessarini RJ. Drugs and the Treatment of Psychiatric Disorders. Depression and Mania. In JG Hardman, LE Limbird (eds), Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996;431–459.

52. Physicians' Desk Reference. Montvale, NJ: Medical Economics Co, 2000.

53. DeVane CL, Nemeroff CB. 1999 Guide to Psycho- tropic Drug Interactions. In DC Steffens, KR Krishnan, PM Doraiswamy (eds), The Psychotropic Drug Interactions Reference Guide (vol 4–6). Primary Psychiatry, 1997–1999. New York: McMahon Publishing Group.

54. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835–847.

55. Asconapé J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479–481.

56. Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999;40[Suppl 10]:S71–S76.

57. Devinsky O, Duchowny MS. Seizures after convulsive therapy: a retrospective case survey. Neurology 1983;33:921–925.

58. Hsiao JK, Messenheimer JA, Evans DL. ECT and neurological disorders. Convulsive Ther 1987;3:121–136.

59. Harden CL, Pulver MC, Ravdin LD, et al. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000;1:93–99.

60. Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999;40[Suppl 10]:S65–S70.

61. Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967;17:869–877.

62. Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures. An in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982;39:206–209.

63. Starr MS. The role of dopamine in epilepsy. Synapse 1996;22:159–194.

64. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of -aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25:213–220.

65. Henrickson O. An overview of benzodiazepines in seizure management. Epilepsia 1998;39[Suppl 1]:S2–S6.

66. Tassinari CA, Michelucci R. The use of diazepam and clonazepam in epilepsy. Epilepsia 1989;39[Suppl 1]:S7–S14.

67. Gillin JC, Byerley WF. The diagnosis and management of insomnia. N Engl J Med 1990;322:239–248.

68. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reactions after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854–859.

69. Preskorn SH, Denner LJ. Benzodiazepines and withdrawal psychosis. JAMA 1977;237:36–38.

70. Noyes R. Seizures following the withdrawal of alprazolam. J Nerv Ment Dis 1986;174:50–52.

71. Dooley JM. Rectal use of benzodiazepines. Epilepsia 1998;39:[Suppl 1]:S24–S27.

72. Fitzgerald J, Anderson M. Focus on flumazenil: a new benzodiazepine antagonist. Hosp Formul 1992;27:575–583.

73. Feeney DJ, Klykylo WM. Medication-induced seizures [Letter]. J Am Acad Child Adolesc Psychiatry 1997;36:1018–1019.

74. Brust JC. Amphetamine and Other Psychostimulants. In JC Brust (ed), Neurological Aspects of Substance Abuse. Boston: Butterworth–Heinemann, 1993;60–81.

75. Derlet RW, Albertson TE, Rice P. Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav 1990;36:745–749.

76. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996;94:367–377.

77. Perucca E, Gram L, Avanzine G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5–17.

78. Loiseau P. Do antiepileptic drugs exacerbate seizures? Epilepsia 1998;39:2–4.

79. Schacter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine. Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999;52:732–737.

80. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236–242.

81. Buckley NA, Whyte IM, Dawson AH, Cruickshank DA. Pheniramine—a much abused drug. Med J Aust 1994;160:188–192.

82. Zimmerman PM, Pulliam J, Schwengels J, MacDonald SE. Caffeine intoxication: a near fatality. Ann Emerg Med 1985;14:1227–1229.

83. Centers for Disease Control and Prevention. Adverse events associated with ingestion of gamma-butyrolactone—Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:137–140.

84. Yates SW, Viera AJ. Physostigmine in the treatment of -hydroxybutyric acid overdose. Mayo Clin Proc 2000;75:401–402.

85. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999;59:1239–1244.

86. Angell M, Kassirer JP. Alternative medicine: the risk of untested and unregulated remedies. N Engl J Med 1998;339:839–841.

87. Alldredge BK, Lowenstein DH. Status epilepticus related to alcohol abuse. Epilepsia 1993;34:1033–1037.

88. McMicken DB, Freedland ES. Alcohol-related seizures. Management of seizures in the ED. Emerg Med Clin North Am 1994;12:1057–1077.

89. Brust JC. Ethanol. In JC Brust (ed), Neurological Aspects of Substance Abuse. Boston: Butterworth-Heinemann, 1993;190–252.

90. Menzano E, Carlen PL. Zinc deficiency and corticosteroids in the pathogenesis of alcoholic brain dysfunction—a review. Alcohol Clin Exp Res 1994;18:895–901.

91. Saito T, Kobatake K, Ozawa H, Ogata M. Aromatic and branched-chain amino acid levels in alcoholics. Alcohol Alcohol 1994;29[Suppl 1]:133–135.

92. Ng SKC, Hauser WA, Brust JC, Susser M. Alcohol consumption and withdrawal in new-onset seizures. N Engl J Med 1988;319:666–673.

93. Pascual-Leone A, Dhuna A, Altafullah I, Anderson DC. Cocaine-induced seizures. Neurology 1990;40:404–407.

94. Brust JC. Cocaine. In JC Brust (ed), Neurological Aspects of Substance Abuse. Boston: Butterworth-Heinemann, 1993;82–114.

95. Barat SA, Abdel-Rahman MS. Decreased cocaine- and lidocaine-induced seizure response by dextromethorphan and DNQX in rat. Brain Res 1997;756:179–183.

96. Shimosato K, Watanabe S, Marley R, Saito T. Increased polyamine levels and changes in the sensitivity to convulsions during chronic treatment with cocaine in mice. Brain Res 1995;684:243–247.

97. Ritz MC, George FR. Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharm Exp Ther 1993;264:1333–1343.

98. Ye JH, Liu PL, Wu WH, McArdle JJ. Cocaine depresses GABAA current of hippocampal neurons. Brain Res 1997;770:169–175.

99. Koppel BS, Daras M, Samkoff L. Phenytoin neurotoxicity from illicit use. Neurology 1995;45:198.

100. Crosby RD, Pearson VL, Eller C, et al. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin Pharmacol Ther 1996;59:458–468.

101. Sofuoglu M, Pentel PR, Bliss RL, et al. Effects of phenytoin on cocaine self-administration in humans. Drug Alcohol Depend 1999;53:273–275.

102. Koppel BS, Samkoff L, Daras M. Relation of cocaine use to seizures and epilepsy. Epilepsia 1996;37:875–878.

103. Derlet RW, Albertson TE. Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications. Ann Emerg Med 1994;23:494–498.

104. Abramowicz M, ed. Acute reactions to drugs of abuse. Med Lett 1996;38:43–46.

105. Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med J 1999;75:32–33.

106. Ng SK, Brust JC, Hauser WA, Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 1990;132:47–57.

107. Brust JC. Opioids. In JC Brust (ed), Neurological Aspects of Substance Abuse. Boston: Butterworth-Heinemann, 1993;16–59.

108. Tobias JD. Seizure after overdose of tramadol. South Med J 1997;90:826–827.

109. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 1999;24:115–123.

110. Ng B, Alvear M. Dextropropoxyphene addiction—a drug of primary abuse. Am J Drug Alcohol Abuse 1993;19:153–158.

Acknowledgment: Dr. Srivalli Denthireni assisted with library research for this section.

Adapted from: Koppel BS. Contribution of drugs and drug interactions (prescribed, over the counter, and illicit) to seizures and epilepsy. In: Ettinger AB and Devinsky O, eds. Managing epilepsy and co-existing disorders. Boston: Butterworth-Heinemann; 2002;155–173. With permission from Elsevier (www.elsevier.com).

Authored By: 
Barbara S. Koppel MD
Reviewed By: 
Steven C. Schachter MD
Sunday, February 29, 2004